2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2110

Association of Systemic Lupus Erythematosus (SLE) Genetic Susceptibility Loci with Lupus Nephritis in Children and Adults with SLE
Abstract Number: 2119

Association of the Variant Form of rs17408553 at Human Leukocyte Antigen-C Supports Evidence That Hypo-Responsive Natural Killer Cells Adversely Influence the Course of Nephritis
Abstract Number: 2147

Associations between Current Cigarette Smoking and SLE-Related Cytokine and Chemokine Biomarkers Among U.S. Female Nurses without SLE
Abstract Number: 1081

Associations between Daily Alcohol Intake and SLE-Related Cytokines and Chemokines U.S. Female Nurses without SLE
Abstract Number: 1509

Associations between Perceived Stress and Joint Signs in an Anti-Cyclic Citrullinated Peptide Antibody Positive at-Risk Population
Abstract Number: 2847

Associations between Serum Uric Acid Level and Coronary Artery Disease
Abstract Number: 895

Associations of Statin Usage with Disease Activity in Ankylosing Spondylitis
Abstract Number: 1752

Asthma in Eosinophilic Granulomatosis with Polyangiitis Treated with Rituximab
Abstract Number: 1355

Asymptomatic Hyperuricemia Is Associated with Increased Prevalence of Symptomatic Knee Osteoarthritis: Data from Third National Health and Nutrition Examination Survey
Abstract Number: 601

At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials
Abstract Number: 2642

Atacicept Dose Rationale for a Phase 3 Study in Patients with High Disease Activity and Auto-Antibody Positive SLE
Abstract Number: 737

Atherogenic Index of Plasma in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A 10-Year Potential Predictor of Cardiovascular Disease
Abstract Number: 1596

Atherosclerotic Cardiovascular Disease in Psoriatic Arthritis: Evaluation of Risk Factor Management and Use of Aspirin and Statin for Prevention in a Primary Care Setting
Abstract Number: 2203

Atherosclerotic Inflammation in Rheumatoid Arthritis Patients: A Post-Hoc Study Using Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
Abstract Number: 729

Atherosclerotic Vascular Events in SLE – an Evolving Story

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].